Phase 2 N=8 Treatment

A Study in Subjects With Retinitis Pigmentosa

Retinitis Pigmentosa

Bottom Line

View on ClinicalTrials.gov: NCT05392179 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2026

Primary outcome: Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: ADX-2191 (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Aldeyra Therapeutics, Inc.
Primary completion: Jun 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Subjects With Serious Adverse Events	0; 0	—

Summary

An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.

Eligibility Criteria

Inclusion Criteria

Up to 8 adult patients age 18 or older
Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H
Impairment on Visual Field as determined by perimetry

Exclusion Criteria

Age < 18 years
Pregnant
Previous inflammatory/infectious events involving the eyes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05392179). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.